Intranasal dexmedetomidine in artificial abortion-vacuum aspiration

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007141

Enrollment

Unknown

Registered

2015-09-21

Start date

2015-11-13

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sedation in artificial abortion

Interventions

P:propofol

SP:propofol+sulfentanil

DP:propofol+dexmedetomidine

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 18-35 years old, pregnancy of 8-10 weeks, ASA I-II, who were undergoing elective artificial abortion-vacuum aspiration in the clinic of gynaecology andobstetrics of Dalian medical university.

Exclusion criteria

Exclusion criteria: Patients with known allergy or regular use of dexmedetomidine, opoids andpropofol, sedatives, andhistory of abortion or labor, impaired liver or renal function, alcohol consumption in excess 28 units per week, known psychological disorder, asthma, heart disease, BMI more than 24kg/m2, sleep apnea syndrome andpatient refusal were excluded

Design outcomes

Primary

Measure	Time frame
dosage of propofol;	—

Secondary

Measure	Time frame
S-AI;NRS anxiety score;	—

Countries

China

Contacts

Public ContactJun-yu Xiong

jyxiong0639@163.com+86 13942079839

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026